CompletedEUCTR 2015-003035-35

An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients with Opioi...

This historical record does not confirm current site availability.

Historical research recordMultiple countriesAddiction

The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Denmark · Hungary and 2 more locations
Study phase: Phase 3

Get this study by email

Study clarity

Study information

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: 228
Sponsor: Braeburn Pharmaceuticals
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United Kingdom, Denmark, Hungary, ...
Age range: Not clearly listed
Official registry ID: EUCTR 2015-003035-35
Official title: Show the full official title
An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients with Opioi...

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Denmark · Hungary · Sweden

1 more locations

United Kingdom

Registry details

Historical country statuses

Denmark — Completed
United Kingdom — Completed
Hungary — Completed
Sweden — Completed

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Braeburn Pharmaceuticals.

Want to explore more studies?

Explore studies